Actelion Ltd. News Conference As Drugmaker Agrees $30 Takeover Billion With Johnson & Johnson

Joaquin Duato, executive vice president at Johnson & Johnson, speaks during a news conference to announce Johnson & Johnson takeover of Actelion Ltd., at the Actelion headquarter offices in Allschwil, Switzerland, on Thursday, Jan. 26, 2017. Johnson & Johnson agreed to buy Actelion for $30 billion and spin off the Swiss drugmaker's research and development operations, clinching its largest deal ever to become a leader in medicines for a rare type of high blood pressure. Photographer: Michele Limina/Bloomberg via Getty Images